CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02505984
NCT02505984Phase 2Completed
CompareCT.gov

Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD

Massachusetts General Hospital·interventional·Posted Jul 22, 2015·Updated Feb 25, 2025

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Depression, Postpartum and Anxiety. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to test a new treatment for preventing childbirth-related mental illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development. To this end, the investigators will test the clinical utility of intranasal (IN) oxytocin (OXT) administered to mothers during the first postpartum days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Postpartum, Anxiety
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 22, 2015
Enrollment StartJan 1, 2016
Primary CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 10.9 years ago

Interventions

Oxytocindrug

Study participants will be randomized to a placebo or drug group.

Placebodrug

Study participants will be randomized to a placebo or drug group.